Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Indivior ( (INDV) ) has provided an announcement.
On October 1, 2025, Indivior PLC announced its intention to redomicile from the U.K. to the U.S. by establishing a new parent company, Indivior Pharmaceuticals, Inc., in Delaware. This strategic move follows its Nasdaq listing and aims to enhance its U.S. capital market presence, simplify governance, and align with U.S. health policy stakeholders. The redomiciliation process involves a U.K. court-sanctioned scheme of arrangement and requires shareholder approval, with the transition expected to be completed by late January 2026. This change is anticipated to position Indivior as a U.S.-based treatment innovator, facilitating collaboration on advancing its opioid use disorder treatment, SUBLOCADE®.
The most recent analyst rating on (INDV) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
Spark’s Take on INDV Stock
According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.
Indivior’s overall stock score is driven by strong earnings call performance and positive corporate events, offset by financial instability and lack of technical analysis data. The company’s strategic initiatives and improved guidance provide a positive outlook, but financial and valuation concerns remain.
To see Spark’s full report on INDV stock, click here.
More about Indivior
Indivior is a pharmaceutical company focused on developing medicines to treat opioid use disorder (OUD). The company aims to transform OUD from a crisis into a recognized and treated chronic disease, with a portfolio of treatments and a pipeline of product candidates in this category.
Average Trading Volume: 2,891,126
Technical Sentiment Signal: Buy
Current Market Cap: $3.01B
Learn more about INDV stock on TipRanks’ Stock Analysis page.